ReviewNature reviews. Genetics2018
Towards quantitative and multiplexed in vivo functional cancer genomics.
Review in Nature reviews. Genetics, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 39 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
39 citing papers in PubMed.
- Generation of a stable mouse endometrial tumor-derived cell line using conditional reprogramming.Biological research · 2026Article
- Exploring the versatility ofFly · 2025Review
- Combinatorial In Vivo Genome Editing Identifies Widespread Epistasis and an Accessible Fitness Landscape During Lung Tumorigenesis.Molecular biology and evolution · 2025Article
- How CRISPR Is Revolutionizing the Generation of New Models for Cancer Research.Cold Spring Harbor perspectives in medicine · 2024Review
- Oncogenic context shapes the fitness landscape of tumor suppression.Nature communications · 2023Article
- High-Throughput Identification, Modeling, and Analysis of Cancer Driver Genes In Vivo.Cold Spring Harbor perspectives in medicine · 2023Review
- Dissecting metastasis using preclinical models and methods.Nature reviews. Cancer · 2023Review
- Microfluidics guided by deep learning for cancer immunotherapy screening.Proceedings of the National Academy of Sciences of the United States of America · 2022Article
- Integrated screens uncover a cell surface tumor suppressor geneProceedings of the National Academy of Sciences of the United States of America · 2022Article
- Quantitative In Vivo Genetic Analysis Reveals Novel Genetic Determinants of Tumor Initiation, Overall Growth, and Exceptional Growth in KRAS-Driven Lung Cancer.Global medical genetics · 2022Article
- Article
- Combinatorial Inactivation of Tumor Suppressors Efficiently Initiates Lung Adenocarcinoma with Therapeutic Vulnerabilities.Cancer research · 2022Article
- A new era in functional genomics screens.Nature reviews. Genetics · 2022Review
- Harnessing the predictive power of preclinical models for oncology drug development.Nature reviews. Drug discovery · 2022Review
- X-box Binding Protein 1 is a Potential Immunotherapy Target in Ovarian Cancer.Frontiers in genetics · 2022Article
- Tumor suppressor pathways shape EGFR-driven lung tumor progression and response to treatment.Molecular & cellular oncology · 2022Article
- QuantitativeCancer research · 2021Article
- A Functional Taxonomy of Tumor Suppression in Oncogenic KRAS-Driven Lung Cancer.Cancer discovery · 2021Article
- Genetic Determinants of EGFR-Driven Lung Cancer Growth and Therapeutic ResponseCancer discovery · 2021Article
- CRISPR screens in physiologic medium reveal conditionally essential genes in human cells.Cell metabolism · 2021Article
Corrections and comments
- Erratum issued
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Large-scale sequencing of human tumours has uncovered a vast array of genomic alterations. Genetically engineered mouse models recapitulate many features of human cancer and have been instrumental in assigning biological meaning to specific cancer-associated alterations. However, their time, cost and labour-intensive nature limits their broad utility; thus, the functional importance of the majority of genomic aberrations in cancer remains unknown. Recent advances have accelerated the functional interrogation of cancer-associated alterations within in vivo models. Specifically, the past few years have seen the emergence of CRISPR-Cas9-based strategies to rapidly generate increasingly complex somatic alterations and the development of multiplexed and quantitative approaches to ascertain gene function in vivo.
Indexed as
Identifiers
30267031What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.